Literature DB >> 18752719

A comparison of RUL ultrabrief pulse (0.3 ms) ECT and standard RUL ECT.

Colleen K Loo1, Kirby Sainsbury, Patrick Sheehan, Bill Lyndon.   

Abstract

An important goal in electroconvulsive therapy (ECT) research is to minimize associated cognitive side-effects while maintaining its high efficacy. This study explored the use of a novel approach, right unilateral (RUL) ECT with an ultrabrief pulsewidth (0.3 ms) (RUL-UB), in comparison with standard RUL ECT. Seventy-four depressed in-patients received RUL-UB ECT at six times seizure threshold, and 22 patients received standard RUL ECT (1.0 ms pulsewidth) at five times seizure threshold. Formal, prospective evaluations of mood and cognitive functioning over the treatment course were done by a rater blinded to treatment condition. Efficacy was maintained using the ultrabrief pulsewidth, with equivalent numbers of responders and remitters to the standard RUL ECT group, although the speed of response was slower. Cognitive outcomes were superior in the RUL-UB ECT group, particularly in the retention of verbal and visual information, as well as in retrograde autobiographical memory.

Entities:  

Mesh:

Year:  2008        PMID: 18752719     DOI: 10.1017/S1461145708009292

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  27 in total

Review 1.  Brain stimulation in psychiatry and its effects on cognition.

Authors:  Kate E Hoy; Paul B Fitzgerald
Journal:  Nat Rev Neurol       Date:  2010-04-06       Impact factor: 42.937

2.  Seizure threshold increases can be predicted by EEG quality in right unilateral ultrabrief ECT.

Authors:  Verònica Gálvez; Dusan Hadzi-Pavlovic; Susan Waite; Colleen K Loo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-11       Impact factor: 5.270

3.  [Electroconvulsive therapy. Indications, procedure and treatment results].

Authors:  H W Folkerts
Journal:  Nervenarzt       Date:  2011-01       Impact factor: 1.214

4.  A review of ultrabrief pulse width electroconvulsive therapy.

Authors:  Colleen K Loo; Natalie Katalinic; Donel Martin; Isaac Schweitzer
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

5.  Magnetic seizure therapy is efficacious and well tolerated for treatment-resistant bipolar depression: an open-label clinical trial

Authors:  Victor M. Tang; Daniel M. Blumberger; Julia Dimitrova; Alanah Throop; Shawn M. McClintock; Daphne Voineskos; Jonathan Downar; Yuliya Knyahnytska; Benoit H. Mulsant; Paul B. Fitzgerald; Zafiris J. Daskalakis
Journal:  J Psychiatry Neurosci       Date:  2020-09-01       Impact factor: 6.186

Review 6.  Neuromodulation therapies for geriatric depression.

Authors:  Verònica Gálvez; Kerrie-Anne Ho; Angelo Alonzo; Donel Martin; Duncan George; Colleen K Loo
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

7.  A systematic review of the neurocognitive effects of magnetic seizure therapy.

Authors:  Shawn M McClintock; Owais Tirmizi; Matthieu Chansard; Mustafa M Husain
Journal:  Int Rev Psychiatry       Date:  2011-10

8.  Brief vs. ultrabrief pulse ECT: focus on seizure quality.

Authors:  Isabelle Brunner; Michael Grözinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-07-18       Impact factor: 5.270

9.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

10.  Brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy (ECT) for major depression: efficacy, effectiveness, and cognitive effects.

Authors:  Charles H Kellner; Shawn M McClintock; W Vaughn McCall; George Petrides; Rebecca G Knapp; Richard D Weiner; Robert C Young; Robert M Greenberg; Matthew V Rudorfer; Gabriella M Ahle; Lauren S Liebman; Sarah H Lisanby
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.